PT  - JOURNAL ARTICLE
AU  - Laura Ibanez
AU  - Jorge A. Bahena
AU  - Chengran Yang
AU  - Umber Dube
AU  - Fabiana G. Farias
AU  - John P. Budde
AU  - Kristy Bergmann
AU  - Carol Brenner-Webster
AU  - John C. Morris
AU  - Richard J. Perrin
AU  - Nigel Cairns
AU  - John O’Donnell
AU  - Ignacio Álvarez
AU  - Monica Diez-Fairen
AU  - Miquel Aguilar
AU  - Rebecca Miller
AU  - Albert A. Davis
AU  - Pau Pastor
AU  - Paul Kotzbauer
AU  - Meghan C. Campbell
AU  - Joel S. Perlmutter
AU  - Herve Rhinn
AU  - Oscar Harari
AU  - Carlos Cruchaga
AU  - Bruno A. Benitez
TI  - Genome-wide association, Mendelian Randomization and polygenic risk score studies converge on a role of β−amyloid and <em>APOE</em> locus in Parkinson disease
AID  - 10.1101/2020.07.01.20144493
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.01.20144493
4099  - http://medrxiv.org/content/early/2020/07/03/2020.07.01.20144493.short
4100  - http://medrxiv.org/content/early/2020/07/03/2020.07.01.20144493.full
AB  - Alpha-Synuclein (α-Syn) is the main protein component of Lewy bodies (LB), the pathological hallmark of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of α-Syn are not currently used as a clinical biomarker but may be a proxy for pathological α-Syn accumulation in the brain. Therefore, identifying genetic modifiers of CSF α-Syn levels could provide insights into the underlying molecular mechanisms leading to PD. However, genetic modifiers of CSF α-Syn levels remain unknown. CSF levels of amyloid beta1-42 (Aβ42), total tau (t-tau), and phosphorylated tau181 (p-tau181) are standard biomarkers for the diagnosis of Alzheimer disease (AD); its use as quantitative traits in genetic studies have provided novel insights into AD pathophysiology. A systematic study of the genomic architecture of CSF biomarkers in PD has not been conducted. Here, genome-wide association studies (GWAS) were performed using CSF biomarker levels as quantitative traits in four PD cases and control cohorts (combined N=1,960). CSF biomarker (α-Syn, Aβ42, t-tau, and p-tau181) levels were significantly lower in PD cases compared with controls. An SNP, proxy for APOE ε4, was associated with CSF Aβ42 levels (effect=-0.5, p=9.2×10−19). Several genome-wide suggestive loci associated with CSF α-Syn, t-tau, or p-tau181 were found. Polygenic risk scores (PRS) were constructed using the latest PD risk meta-analysis (49,731 PD cases and 784,343 controls) and the largest CSF biomarkers GWAS (N=3,146). PRS calculated using META-PD were associated with PD status in the four cohorts included in the present study (p= 2.2×10−16). A highly significant correlation (Nagelkerke pseudo-R2 =2.29%; p=2.5×10−11) of the genomic architecture between CSF Aβ42 and PD risk was also found. Higher PRS scores were associated with lower CSF Aβ42 levels (p=7.3×10−04). Two-sample Mendelian Randomization (MR) approach revealed that CSF Aβ42 plays a role in PD risk (p=1.4×10−05) and age at onset (p=7.6×10−06), an effect mainly mediated by variants in the APOE locus. Subsequently, the APOE ε4 allele was associated with significantly lower levels of CSF Aβ42 (p=3.8×10−06), higher mean cortical binding potentials (cortical binding of Pittsburgh compound B PET) (p=5.8×10−08) and higher Braak Aβ score (p=4.4×10−04) in PD participants. Together these results from high-throughput and hypothesis-free approaches (GWAS, PRS and MR) converge on a genetic link between PD with CSF Aβ42 and APOE.Competing Interest StatementCC receives research support from Biogen, EISAI, Alector, and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics, and ADx HealthcareFunding StatementThis work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501, R01AG057777, NS097437, NS075321, NS097799 and NS07532), the Alzheimer Association (NIRG-11-200110, BAND-14-338165, AARG-16-441560, and BFG-15-362540), the American Parkinson Disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Jo Riney Fund, the Barnes Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson Disease Research Fund), and the Paula and Roger Riney Fund. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of all participating institutions approved the study, and this research was carried out in accordance with the recommended protocols. Written informed consent was obtained from participants or their family members.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the Center for Neurogenomics and informatics (NGI) website (https://neurogenomics.wustl.edu/). The summary statistics for all the analyses can be easily explored in the Online Neurodegenerative Trait Integrative Multi-Omics Explorer (ONTIME) (https://omics.wustl.edu) and the Charles F. and Joanne Knight Alzheimer Disease Research Center (https://knightadrc.wustl.edu/research/resourcerequest.htm). https://omics.wustl.edu